You searched for Parkinson's - Page 9 of 19

Best in Biotech 13 May 2025

Nine biotech companies in Montreal to keep an eye on in 2025

…plays a crucial role in regulating appetite and energy balance – followed by one for Parkinson’s disease targeting GCase – an enzyme linked to Parkinson’s – and another candidate to…

May 13, 2025 - 11 minutesmins - By Roohi Mariam Peter

News and Trends 28 May 2021

Startup Creator Launched to Fill Europe’s Microbiome Translational Gap

…Ysopia Bioscience – are based in Europe. Stellate’s lead asset is a metabolite produced by gut bacteria with neuroprotective qualities. The candidate is on track for clinical trials for Parkinson’s…

May 28, 2021 - 6 minutesmins - By Mark Zipkin

News and Trends 16 Oct 2017

Interview: On the Future of iPS Cells and why Partnering is so Important in this Field

…be differentiated into pancreatic beta cells in the case of diabetes, or dopaminergic neurons in the case of Parkinson’s disease, and then be transplanted back into patients to replace their…

October 16, 2017 - 9 minutesmins - By External Contributor

In Depth 21 Aug 2024

The promise of antisense oligonucleotides in precision medicine

…α-synuclein and improve symptoms in a mouse model of Parkinson’s disease. Parkinson’s disease has shown a link between the abnormal aggregation of α-synuclein and neuronal death. These aggregates are known…

August 21, 2024 - 11 minutesmins - By Willow Shah-Neville

News and Trends 14 Dec 2022

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

…formerly CEO at regenerative medicine company, Aspen Neuroscience, Inc. Joe Glorioso, the inventor of synHSV, is also a co-founder of Kaleibe. The initial development programs will focus on genetic Parkinson’s…

December 14, 2022 - 4 minutesmins - By Jim Cornall

Best in Biotech 23 May 2025

Finland: Pushing biotech forward in the land of a thousand lakes

…enabling subcutaneous administration while retaining the neuroprotective properties of CDNF. HER-096 targets the unfolded protein response and brain inflammation triggered by alpha-synuclein aggregation, key factors in the progression of Parkinson’s…

May 23, 2025 - 10 minutesmins - By Jules Adam

Libra Therapeutics, the virtual biotech company using data to boost CNS drug development

How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases

…in-person therapeutic index.” Initial indications for its lead TRPML1 program will likely be ALS and Parkinson’s disease, although Gill believes there is much wider potential. “There may be an opportunity…

February 25, 2025 - 9 minutesmins - By External Contributor

Discovering New Therapeutic Targets for Alzheimer’s Disease

…disease models, and patient-derived cell lines, as well as a variety of sophisticated animal models for Alzheimer’s, Parkinson’s disease, encephalomyelitis, and amyotrophic lateral sclerosis. “As our understanding of genomics and…

September 22, 2021 - 7 minutesmins - By Julia Kaiser

News and Trends 23 Jun 2023

SandboxAQ launches new division to boost drug development

…in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and UC San Francisco. Paul Hudson,…

June 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

…figure is expected to double every 20 years as the population ages. The total direct and informal care costs of Alzheimer’s, Parkinson’s and related disorders are expected to surpass €350…

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 15 Nov 2022

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract…

November 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jun 2018

Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder

…a range of treatments targeting other indications, including type 2 diabetes, cocaine addiction and Parkinson’s disease. Last year, the company started a Phase III trial for Tesofine, the most advanced…

June 11, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Parkinson's

Nine biotech companies in Montreal to keep an eye on in 2025

Startup Creator Launched to Fill Europe’s Microbiome Translational Gap

Interview: On the Future of iPS Cells and why Partnering is so Important in this Field

The promise of antisense oligonucleotides in precision medicine

Replay targets genetic brain disorders with new gene therapy company, Kaleibe

Finland: Pushing biotech forward in the land of a thousand lakes

How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases

Discovering New Therapeutic Targets for Alzheimer’s Disease

SandboxAQ launches new division to boost drug development

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS

Danish Biotech Plans Phase II Study to Fight A Rare Eating Disorder

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!